There is a concept of therapy that tries to identify compounds or hormones that antagonize the effect of human growth hormone, and tries to foil them. This might be considered the medical equivalent of a double negative or "the enemy of my friend is my enemy". The body produces a hormone called somatostatin. This hormone is the antithesis of human growth hormone. Therapeutic attempts have been made to attack somatostatin function in hopes of freeing the human growth hormone that is already present for a net increase in human growth hormone function or effect. These anti-somatostatin treatments have been intellectually honest but of disappointing effect; typically showing a 1% or so rise in IGF-1 levels, and no measurable clinical difference in patient outcomes. There is no current recommendation favoring the use of these compounds.